Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Kevin Kotler & Broadfin Capital Take a 5.2% Stake in Biodel

Biodel, Broadfin Capital: In a 13G filing reported a few minutes ago, Kevin Kotler‘s Broadfin Capital disclosed ownership of a 5.2% stake in Biodel Inc (NASDAQ:BIOD), a company engaged in the development of diabetes treatments. Broadfin is a hedge fund almost entirely focused in healthcare, with the majority of its $500 million equity portfolio invested in this space.

Kevin Kotler

At the beginning of September, Biodel disclosed positive news on its BIOD-123 phase 2 clinical study. BIOD-123 is “an investigational ultra-rapid-acting mealtime insulin, in patients with type 1 diabetes,” which “achieved the primary endpoint of non-inferiority for HbA1c relative to insulin lispro, a widely prescribed rapid acting mealtime insulin analog marketed as Humalog® ,” Biodel said in a statement.

In the third fiscal quarter, Biodel posted a net loss of $9.6 million, equal to $0.66 per share, expanding it from the $6.1 million net loss posted for the same three months of 2012.

Samuel Isaly‘s Orbimed Advisors helds the largest stake in Biodel, out of the funds we track. Its position contains almost 2.7 million shares.

Disclosure: none

Recommended Reading:

Nevada Capital Cuts Genco Shipping & Trading Significantly

Heartland Advisors Discloses a 1.9% Stake in Lantronix

Fort Dearborn Receives Vote of Confidence From Karpus Management


Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!